CN103044576B - Method for improving stability of heparin sodium - Google Patents
Method for improving stability of heparin sodium Download PDFInfo
- Publication number
- CN103044576B CN103044576B CN201210549739.9A CN201210549739A CN103044576B CN 103044576 B CN103044576 B CN 103044576B CN 201210549739 A CN201210549739 A CN 201210549739A CN 103044576 B CN103044576 B CN 103044576B
- Authority
- CN
- China
- Prior art keywords
- heparin sodium
- stability
- reductive agent
- product
- feed liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a technical method for improving stability of heparin sodium. At present, a hydrogen peroxide oxidizing method is generally used for decoloring in a heparin sodium refining process; the prepared heparin sodium product contains residual peroxy ions (O22-); the stability of the product is affected in the heparin sodium storage process; and the biological value of the product is reduced. The method for improving the stability of the heparin sodium, provided by the invention, has the advantages as follows: through the adoption of a low temperature reduction method, residual oxygen ions generated in the refining process are removed and the product stability is improved.
Description
Technical field
The present invention relates to a kind of raising stability of heparin sodium method, particularly a kind of heparin sodium production process.
Background technology
Heparin sodium is a kind of clinical conventional anticoagulation medicine, the mucopolysaccharide material mainly extracted from pig intestinal mucosa, has anticoagulation and prevent thrombotic effect significantly.The emerging in large numbers of low molecular sodium heparin product in recent years, makes the application of heparin sodium more and more extensive.Current heparin sodium industry is generally applied hydrogen peroxide oxidation process and is refined, and this technique comparatively potassium permanganate oxidation has sent out plurality of advantages, and technique is simple, and oxidation efficiency is high.But be also faced with the residue problem of peroxide radical ion simultaneously, bring challenges to the stability of heparin sodium.
Summary of the invention
Object of the present invention provides a kind of reductive agent to remove the method for residual oxygen radical ion in refining heparin sodium, overcomes the stability problem that hydrogen peroxide oxidation method for refining brings.
Object of the present invention reaches by the following technical programs, is realized successively by following step.
1, the heparin sodium refining through hydrogen peroxide is dropped in retort, dissolve in the ratio purified water of 1: 10 (w/w);
2, be cooled to 10-15 DEG C, adjust pH=9.0-10.0, add reductive agent A or reductive agent B in the ratio of 3-5%, insulation leaves standstill 10-12 hour;
3, feed liquid is filtered;
4, by the feed liquid after filtration, regulate pH=5.0-5.5, add sodium-chlor by 2-4% (w/v), adding 95% ethanol to alcohol concn is afterwards 38-45%, leaves standstill 10-12 hour, throw out dehydration post-drying.
The beneficial effect of the technical program is: the stability of heparin sodium product can be evaluated by accelerated test and long-term stable experiment data.The inventive method product through 6 months accelerated tests (temperature 40 ± 2 DEG C, relative humidity 75 ± 5%), titer of heparin sodium reduction≤2U/mg; Through 2 years long-term stable experiments, titer of heparin sodium reduction≤3U/mg.Without the obtained product of the traditional method of reduction through 6 months accelerated tests (temperature 40 ± 2 DEG C, relative humidity 75 ± 5%), titer of heparin sodium reduction >=6U/mg; Through 2 years long-term stable experiments, titer of heparin sodium reduction >=10U/mg, contrast was as following table.
The first, in the technical program, adding the temperature before reductive agent must be down to 10-15 DEG C, reflection mild condition.
The second, in the technical program, reductive agent A is V-Brite B, after diluting with gac or talcum powder, reduction reaction gentleness can be made to carry out.
3rd, in the technical program, reductive agent B is Sulfothiorine, after diluting with gac or talcum powder, reduction reaction gentleness can be made to carry out.
Embodiment
Following instance describes the present invention in detail:
1, by the heparin sodium 50Kg through hydrogen peroxide oxide purification, join in retort, add 500Kg purified water and fully dissolve.
2, be cooled to 15 DEG C, regulate pH=9.5, add reductive agent A22g (11g V-Brite B fully mixes with 11g gac), after stirring, stand at low temperature 10-12 hour.
3, feed liquid filter press device is filtered (millipore filtration aperture is 0.8 μm).
4, by the feed adjustment pH=5.0 after filtering, adding 16.5Kg sodium-chlor, is 40% with 95% alcohol settling to alcohol concn afterwards, leaves standstill 10 hours, and post-drying of dewatering, must have good stability heparin sodium.
Claims (1)
1. improve a method for stability of heparin sodium, it is characterized in that:
(1) heparin sodium refining through hydrogen peroxide is dropped in retort, dissolve by the mass ratio purified water of 1: 10;
(2) be cooled to 10-15 DEG C, adjust pH=9.0-10.0, add reductive agent A or reductive agent B in the ratio of 3-5%, insulation leaves standstill 10-12 hour;
(3) feed liquid is filtered;
(4) by the feed liquid after filtration, regulate pH=5.0-5.5, add sodium-chlor by 2-4% (w/v), adding 95% ethanol to alcohol concn is afterwards 38-45%, leaves standstill 10-12 hour, throw out dehydration post-drying;
Reductive agent A is V-Brite B and gac or V-Brite B and talcous mixture;
Reductive agent B is Sulfothiorine and gac or Sulfothiorine and talcous mixture;
Feed liquid is filtered into filters with filter press device, millipore filtration aperture≤0.8 μm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210549739.9A CN103044576B (en) | 2012-12-07 | 2012-12-07 | Method for improving stability of heparin sodium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210549739.9A CN103044576B (en) | 2012-12-07 | 2012-12-07 | Method for improving stability of heparin sodium |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103044576A CN103044576A (en) | 2013-04-17 |
CN103044576B true CN103044576B (en) | 2015-07-15 |
Family
ID=48057457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210549739.9A Active CN103044576B (en) | 2012-12-07 | 2012-12-07 | Method for improving stability of heparin sodium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103044576B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114276473A (en) * | 2020-09-27 | 2022-04-05 | 上海帕尼生物科技有限公司 | Refined heparin sodium product and extraction method and application thereof |
-
2012
- 2012-12-07 CN CN201210549739.9A patent/CN103044576B/en active Active
Non-Patent Citations (2)
Title |
---|
张万忠.肝素精制及低分子量肝素的制备.《中国优秀硕士学位论文全文数据库(硕士)工程科技I辑》.2005,(第2期), * |
林灿煌,张灿河.正交试验设计优化脱氧剂配方.《福建化工》.2003,(第4期), * |
Also Published As
Publication number | Publication date |
---|---|
CN103044576A (en) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103044577A (en) | Method for reducing dermatan sulfate content in heparin sodium product | |
CN106381319B (en) | Efficient extraction and separation method for grape seed procyanidin oligomers | |
CN101434608B (en) | Preparation of high-purity ellagic acid | |
WO2011075534A3 (en) | Purification of isoprene from renewable resources | |
MY149879A (en) | Process for producing acrylic acid, apparatus for producing acrylic acid, and composition for producing acrylic acid | |
WO2011132729A1 (en) | Method for producing crystalline iron arsenate starting material liquid from smoke and ash | |
CN103044576B (en) | Method for improving stability of heparin sodium | |
EP1813635A4 (en) | Process for production of polyethers and polymers | |
CN111484539A (en) | Novel process method for extracting hesperidin by alkaline alcohol | |
CN103044578A (en) | Efficient method for refining heparin sodium crude products | |
CN105037473B (en) | A kind of method of the purification sterol from tall oil | |
CN113647623B (en) | Method for improving anthocyanin stability | |
CN1193995C (en) | Method of extracting oligo proanthocyanidin of grape seed | |
CN103102294A (en) | Production method carboxymethyl cysteine | |
CN112940150A (en) | Method for preparing heparin calcium from heparin sodium | |
CN101412710B (en) | Omeprazole sodium compound and preparation thereof | |
CN102924964A (en) | Process for extracting and purifying monascus red pigment without citrinin | |
CN109485558B (en) | Purification method of long-chain dibasic acid | |
CN106927597B (en) | Treatment of waste water from isophorone production comprising neutralization, filtration and downstream chemical oxidation process with subsequent reduction | |
CN102453736A (en) | Method for transforming hyperin into quercetin by enzyme reaction | |
CN108622869B (en) | method for purifying wet-process phosphoric acid by solvent extraction method | |
CN102070686A (en) | Method for extracting rutin from pagodatree flower buds by microwave method | |
CN106748780B (en) | A kind of removal methods of injection Synthetic Oil metal residual | |
CN111732503A (en) | Method for extracting malic acid from calcium malate solution | |
CN1932022A (en) | Process of preparing high purity solanesol with potato leaf as material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 266100 Zhuzhou Road, Laoshan District, Shandong, No. 97, No. Patentee after: Qingdao Jiulong biological medicine group Co., Ltd. Address before: 266100 Zhuzhou Road, Laoshan District, Shandong, No. 97, No. Patentee before: Qingdao Jiulong Bio-Pharmaceutical Co., Ltd. |